We are open as normal during COVID-19 pandemic. Order online, same day shipping out.
WARNING: This product is for research use only, not for human or veterinary use.
SRN-927 is an orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, SERD SRN-927 specifically binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This prevents ER-mediated signaling and inhibits the growth and survival of ER-expressing cancer cells.
Price and Availability
Pricing updated 2020-08-03.
Prices are subject to change without notice.
SRN-927 is not in stock. This product may be available through custom synthesis when its structure is available.